1	Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a
2	steady-state condition: implications for vaso-occlusive crisis, pain, and sensory
3	sensitivity
4	
5	Wei Li ¹ *, Andrew Q Pucka ² , Candice Debats ² , Brandon Reyes ² , Fahim Syed ¹ , Andrew R
6	O'Brien ³ , Rakesh Mehta ³ , Naveen Manchanda ³ , Seethal A Jacob ⁴ , Brandon M Hardesty ⁵ , Anne
7	Greist ^{3,5} , Steven E Harte ⁶ , Richard E Harris ^{6,7} , Qigui Yu ¹ *, Ying Wang ^{2,3} *
8	
9	¹ Department of Microbiology and Immunology, Indiana University School of Medicine,
10	Indianapolis, IN 46202
11	² Department of Anesthesia, Stark Neurosciences Research Institute, Indiana University School
12	of Medicine, Indianapolis, IN 46202
13	³ Division of Hematology/Oncology, Department of Medicine, Indiana University School of
14	Medicine, Indianapolis, IN 46202
15	⁴ Center for Pediatric and Adolescent Comparative Effectiveness Research, Indiana University
16	School of Medicine, Indianapolis, IN 46202
17	⁵ Indiana Hemophilia and Thrombosis Center, Indianapolis, IN 46260
18	⁶ Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of
19	Michigan Medical School, Ann Arbor, MI 48106
20	⁷ Susan Samueli Integrative Health Institute, and Department of Anesthesiology and
21	Perioperative Care, School of Medicine, University of California at Irvine, Irvine, CA 92617
22	
23	*Corresponding authors
24	Address correspondence to Dr. Ying Wang (ywa12@iu.edu), Department of Anesthesia, Indiana
25	University School of Medicine, Stark Neuroscience Building, Rm# 514E, 320 West 15th Street,
26	Indianapolis, IN 46202, Tel: 317-278-5045; Dr. Wei Li (wl1@iupui.edu) or Dr. Qigui Yu

(andyu@iupui.edu), Department of Microbiology and Immunology, Indiana University School of
 Medicine, Medical Science Building, MS267, 635 Barnhill Drive, Indianapolis, IN 46202, Tel:
 317-274-2391.

30

Key words: Sickle cell disease, inflammation, autoantibody, aggregate, steady-state condition,
 vaso-occlusive crisis, pain sensitivity

33

Running title: Inflammation, autoantibody, RBC-leukocyte aggregation, and vaso-occlusive
 crisis in SCD participants

36

37 **Abbreviations:** $\alpha 4\beta 1$, alpha-4 beta-1; **ANA**, anti-nuclear autoantibody; **CDT**, cold detection 38 threshold; CPT, cold pain threshold; CPM, conditioned pain modulation; CRP, C-reactive 39 protein; DC, dendritic cell; EC, endothelial cell; GPA, glycophorin A; HADS, Hospital Anxiety 40 and Depression Scale; **HC**, healthy control; **HCT**, hematocrit; **HDT**, heat detection threshold; 41 Hgb, hemoglobin; HPT, heat pain threshold; LIF, leukemia inhibitory factor; Lu/BCAM, 42 lutheran/basal cell adhesion molecule; **MCV**, mean corpuscular volume; **MCH**, mean 43 corpuscular hemoglobin; MDT, mechanical detection threshold; MFI, median fluorescent 44 intensity; MPO, myeloperoxidase; MPT, mechanical pain threshold; MTS, mechanical temporal 45 summation; PBMC, peripheral blood mononuclear cell; PedsQL, Pediatric Quality of Life 46 Inventory; PMN, polymorphonuclear neutrophil; PPT, pressure pain threshold; PPToI, pressure 47 pain tolerance; **PROMIS**, Patient-Reported Outcomes Measurement Information System; 48 **PROMs**, patient-reported outcome measures; **QoL**: guality of life; **QST**, guantitative sensory 49 testing; **RBC**, red blood cell; **RDW**, red cell distribution width; **SCD**, sickle cell disease; **SLE**, 50 systemic lupus erythematosus; **SSA/Ro60**, Sjögren's Syndrome-related antigen A/Ro60 kDa; 51 **StSt**, steady-state condition; **TSLP**, thymic stromal lymphopoietin; **TSP**, temporal summation of 52 pain; VOC, vaso-occlusive crisis; WBC, white blood cell.

Conflict of interest

55 The authors declare no conflicts of interest that pertain to this manuscript.

57 Abstract

58 This study aimed to comprehensively analyze inflammatory and autoimmune 59 characteristics of patients with sickle cell disease (SCD) at a steady-state condition (StSt) 60 compared to healthy controls (HCs) to explore the pathogenesis of StSt and its impact on 61 patients' well-being. The study cohort consisted of 40 StSt participants and 23 HCs enrolled 62 between July 2021 and April 2023. StSt participants showed elevated white blood cell (WBC) 63 counts and altered hematological measurements when compared to HCs. A multiplex 64 immunoassay was used to profile 80 inflammatory cytokines/chemokines/growth factors in 65 plasma samples from these SCD participants and HCs. Significantly higher plasma levels of 37 66 analytes were observed in SCD participants, with HGF, IL-18, IP-10, and MCP-2 being among 67 the most significantly affected analytes. Additionally, autoantibody profiles were also altered, 68 with elevated levels of anti-SSA/Ro60, anti-Ribosomal P, anti-Myeloperoxidase (MPO), and 69 anti-PM/ScI-100 observed in SCD participants. Flow cytometric analysis revealed higher rates of 70 red blood cell (RBC)/reticulocyte-leukocyte aggregation in SCD participants, predominantly 71 involving monocytes. Notably, correlation analysis identified associations between inflammatory 72 mediator levels, autoantibodies, RBC/reticulocyte-leukocyte aggregation, clinical lab test results, 73 and pain crisis/sensitivity, shedding light on the intricate interactions between these factors. The 74 findings underscore the potential significance of specific biomarkers and therapeutic targets that 75 may hold promise for future investigations and clinical interventions tailored to the unique 76 challenges posed by SCD. In addition, the correlations between vaso-occlusive crisis 77 (VOC)/pain/sensory sensitivity and inflammation/immune dysregulation offer valuable insights 78 into the pathogenesis of SCD and may lead to more targeted and effective therapeutic 79 strategies.

80

81 Introduction

82 Sickle cell disease (SCD) is a lifelong illness that affects multiple organ systems and can 83 cause a range of complications, including acute and chronic pain, anemia, stroke, pulmonary 84 hypertension, and organ damage (1, 2). The clinical manifestations of SCD can be broadly 85 categorized into two phases: the steady-state (StSt) phase, characterized by mild to no 86 symptoms associated with chronic hemolysis and persistent pain (3), and the severe pain and 87 other clinical complications in the acute hemolytic/vaso-occlusive crisis (VOC) phase (4, 5). The 88 acute VOC phase is marked by the sudden onset of severe pain, possibly accompanied with 89 acute chest syndrome and stroke due to the blockage of small blood vessels by sickle-shaped 90 red blood cells (RBCs). Individuals with SCD requiring high doses of opioids to manage VOC 91 confront a series of substantial risks, such as an increased vulnerability to overdose and 92 mortality, the potential development of opioid-induced hyperalgesia, and a compromised quality 93 of life (QoL). Addressing these challenges becomes paramount, emphasizing the urgent need 94 for evidence-based, effective, and safe pain management therapies tailored specifically for 95 SCD. Indeed, pain is the hallmark of SCD, manifesting anywhere in the body and profoundly 96 impacting patients' QoL (6-8). SCD pain can manifest as acute recurrent painful crises 97 associated with VOCs as well as chronic pain with or without nerve damage (7). The painful 98 crisis, which evolves through four phases-prodromal, initial, established, and resolving-is a 99 leading cause of hospitalization and emergency department treatments in SCD (7). 100 SCD is characterized by the presence of sickle-shaped RBCs with altered biophysical and 101 biochemical properties (9). Unlike normal RBCs, which have a biconcave disc shape for 102 flexibility and deformability, sickle-shaped RBCs lose their ability to deform and navigate 103 through small blood vessels efficiently, leading to blockages and reduced blood flow. To 104 compensate for the RBC loss, bone marrow produces more immature RBCs known as

105 reticulocytes, releasing them into circulation and leading to elevated reticulocyte levels in the

106 blood. In SCD participants, reticulocytes express higher levels of surface adhesion molecules 107 such as Lutheran/basal cell adhesion molecule (Lu/BCAM) and alpha-4 beta-1 (α 4 β 1) integrin 108 (10-15). These adhesion molecules facilitate the binding of reticulocytes to the endothelium 109 lining the blood vessels, causing activation of endothelial cells (ECs) and the release of 110 inflammatory molecules (16-18). Moreover, reticulocytes in SCD interact with circulating 111 leukocytes, including polymorphonuclear neutrophils (PMNs) and monocytes, leading to the 112 formation of aggregates and increasing the occurrence of VOCs (19-21). These interactions are 113 primarily mediated by $\alpha 4\beta 1$ integrin and Lu/BCAM, reinforcing their adhesion to the endothelium 114 (9, 22). In vitro studies have demonstrated that sickle-shaped RBCs can also bind to peripheral 115 leukocytes, especially monocytes, via erythroid LW/ICAM-4 and CD44 receptors. These 116 RBC/reticulocyte-leukocyte aggregates interact with ECs, resulting in EC activation (21). Thus, 117 SCD is associated with increased adhesion of RBC/reticulocytes to leukocytes and ECs, which 118 contribute to the complex pathophysiology underlying SCD pain (10-18).

119 Chronic inflammation persists in SCD due to continuous activation of immune cells or 120 autoimmune responses triggered by various factors, such as hemolysis, vaso-occlusion, and 121 sickle-shaped RBC aggregates. Hemolysis is a primary inflammatory trigger in SCD (17). 122 Sickle-shaped RBCs are more fragile and prone to rupture, leading to the chronic release of 123 hemoglobin and other cellular components. Hemoglobin is a potent pro-inflammatory molecule 124 that activates immune cells such as monocytes, macrophages, and dendritic cells (DCs), 125 prompting them to produce pro-inflammatory cytokines such as IL-1 β (23), IL-6 (24), and TNF- α 126 (23). Additionally, heme, an iron-containing component of hemoglobin, can further induce the 127 production of pro-inflammatory cytokines, chemokines, and adhesion molecules by activating 128 NF- κ B and TLR4 signaling pathways, and promote the recruitment of leukocytes and platelets to 129 sites of inflammation, exacerbating the inflammatory response (25). In addition, vaso-occlusion 130 of small blood vessels by sickle-shaped RBCs leads to tissue ischemia and subsequent 131 hypoxia, activating ECs. The activated ECs produce and release pro-inflammatory cytokines

132 and adhesion molecules (26, 27), which recruit lymphocytes to the site of inflammation, further 133 perpetuating the inflammatory response. Furthermore, chronic activation of the coagulation 134 system in SCD participants results in the release of pro-inflammatory mediators such as 135 thrombin, which can activate ECs and promote the recruitment of inflammatory cells. SCD is 136 also associated with oxidative stress, which contributes to inflammation by activating the NF- κ B 137 pathway, leading to the production of pro-inflammatory cytokines and chemokines. Finally, the 138 impact of autoantibodies on inflammation in SCD participants is noteworthy. Chronic hemolysis 139 and cell damage release intracellular components like hemoglobin, heme, and cellular debris 140 into the bloodstream, triggering the production of autoantibodies. These autoantibodies 141 exacerbate inflammation by forming immune complexes that activate pro-inflammatory 142 pathways, recruit immune cells, and contribute to tissue damage. Highlighting the complex 143 pathophysiology that contributes to inflammation in SCD, a recent study quantified serum levels 144 of 27 inflammatory cytokines, chemokine, and growth factors in 27 individuals in StSt, 22 145 individuals in VOC, and 53 healthy individuals (28). The study found that both pro- and anti-146 inflammatory cytokines are involved in the inflammatory response during SCD, regardless of 147 clinical phase (28). This suggests that the dysregulation of cytokine production and balance may 148 play a role in the disease's pathophysiology.

149 The current study represents the initial phase of an ongoing clinical trial (ClinicalTrials.gov, 150 NCT05045820) focused on investigating the clinical efficacy and neurobiological mechanisms of 151 acupuncture analgesia in SCD participants, for which recruitment is ongoing. The primary 152 objective of the current study was to characterize the pain and the underlying immune and 153 inflammatory abnormalities in SCD participants. To achieve this objective, we examined plasma 154 levels of inflammatory cytokines, chemokines, growth factors, soluble receptors, and effector 155 molecules, as well as the profiles of autoantibodies and the aggregation between 156 RBCs/reticulocytes and leukocytes. Moreover, we investigated the association between these 157 analytes and VOCs, patient reported pain- and QoL-related outcomes, and sensory sensitivity.

Our long-term goal is to identify potential mechanisms and therapeutic targets in SCD, gainingan improved understanding of the mechanisms behind acupuncture intervention.

160

161 Materials and Methods

162

163 Study participants

164 This work constitutes an initial part of an ongoing randomized clinical trial in SCD that 165 commenced on June 29, 2021, and is scheduled to conclude on May 31, 2026. The primary 166 inclusion criteria for participant enrollment included: 1) has been diagnosed with SCD. 2) 167 experiencing chronic pain within the last 6 months or encountered at least one VOC within the 168 past 12 months, 3) no recent changes in stimulant medication dosage or initiation, 4) willingness 169 to continue their ongoing treatments, and 5) an agreement to limit using any new medications or 170 treatment methods for pain management throughout the study. The major exclusion criteria 171 included: 1) individuals with COVID-19 suspected or confirmed, 2) recent or ongoing pain 172 management using acupuncture or acupuncture-related techniques within the last 6-months, 173 and 3) presence of a concurrent autoimmune or inflammatory disease such as rheumatoid 174 arthritis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. In addition, 175 participants who received a blood transfusion within the 90 days prior to recruitment were 176 excluded for analyses. Age-, gender-, and ethnicity-matched health subjects without SCD were 177 recruited as healthy controls (HCs). Detailed information regarding the inclusion and exclusion 178 criteria can be found on ClinicalTrials.gov (NCT05045820).

Peripheral blood samples were collected from 40 SCD participants, comprising 17 males and 23 females, with ages ranging from 14 to 73 years. All participants were Black/African American. SCD participants and HCs were enrolled in this study through Indiana University Health hospitals in Indianapolis, the Indiana Hemophilia & Thrombosis Center, community

183 hospitals, and other resources between July 2021 to April 2023. Peripheral blood was collected 184 at StSt phase in heparin-coated tubes (BD Biosciences, Franklin Lakes, NJ) and subsequently 185 separated into plasma and peripheral blood mononuclear cells (PBMCs). PBMCs were either 186 directly used or cryopreserved in liquid nitrogen until use. Plasma samples were stored at -80°C 187 until use. To establish a comparison, we included PBMC and plasma samples from 23 healthy 188 volunteers, matched in terms of age, sex, and race, to serve as HCs. Detailed demographic and 189 clinical characteristics of both SCD participants and HCs are summarized in Table 1. This study 190 was performed with the approval of the Institutional Review Boards (IRB) at Indiana University 191 School of Medicine, and each participant provided written informed consent during the 192 screening visit prior to the subsequent study procedure.

193

194 **Patient-reported outcome measures (PROMs)**

195 The Patient-Reported Outcomes Measurement Information System (PROMIS)-29 196 Questionnaire was used to evaluate pain intensity and interference, as well as physical function 197 (29). Neuropathic pain symptoms were evaluated using the PainDETECT Questionnaire (higher 198 score indicated higher pain) (30, 31). The Widespread Pain Index was used to evaluate the 199 spatial distribution of pain across the body (higher score indicated higher pain) (32, 33). In 200 addition, depression was evaluated using the Hospital Anxiety and Depression Scale (HADS) 201 (higher score indicated higher depression) (34). Physical function was assessed with PROMIS-202 29 (higher score indicated more physical dysfunction) (29). Pain-related QoL was evaluated 203 using the Pediatric Quality of Life Inventory (PedsQL) targeting 3 different age groups (13-18, 204 18-25, or 25+ years old), with higher scores representing better QOL (35). The number of 205 patient-reported VOCs in the preceding 12 months was documented (36, 37). The number of 206 days between blood draw and the most recent or future VOCs was recorded as the time 207 intervals after or before VOCs.

209 Quantitative Sensory Testing (QST)

210 QST is a well-established experimental protocol designed to investigate both ascending 211 excitatory and descending inhibitory aspects of pain processing by assessing an individual's 212 perceptual response to various stimuli (38). QST was performed at up to three different body 213 sites, including the primary testing site(s), which was the area(s) reported as most painful by 214 each patient, along with the dominant-side ventral forearm and/or the dominant-side upper 215 trapezius muscle, as described in previous studies on SCD (38, 39). HCs received primary 216 testing at sites matched with those identified in patients, in addition to testing at the dominant 217 forearm and/or trapezius.

Thermal (heat/cold) Detection/Pain Threshold was determined at each testing site using a TCA11 (QST-Lab, Strasbourg, France) with a thermal probe in contact with the subject's skin surface. The thermode temperature was gradually adjusted from a baseline temperature at a controlled rate of 0.5 - 1 °C/s. Subjects indicated the thermal detection threshold (when they first felt the thermal stimulus) and the hot pain threshold (when they first felt pain from the thermal stimulus). The average of three trials for each test was used for analysis.

224 Mechanical Detection Threshold (MDT)/Mechanical Pain Threshold (MPT) were examined 225 using von Frey monofilaments (Stoelting, Wood Dale, IL) and calibrated pinprick stimuli (MRC 226 Systems GmbH, Heidelberg, Germany) respectively. Each von Frey monofilament was applied 227 three times in ascending sequence until the stimulus was detected in at least two out of three 228 trials. The next lower von Frey monofilament was then applied, and the lowest filament to be 229 detected at least twice was considered the detection threshold. The MPT was determined using 230 different pinprick probes applied to the skin surface of each site. Testing started with a 231 stimulation intensity of 8 mN and in each case, the next higher pinprick stimulator was applied 232 until the perception of "touch" changed its quality towards an additional percept of "sharp",

"pricking," or "stinging." The corresponding intensity represented the first suprathreshold value.
Once the first painful stimulus was perceived, the testing direction was changed step-wise
towards lower stimulus intensities until the first stimulus perceived as "blunt" and no longer as
being "sharp," "pricking" or "stinging" (subthreshold value). Again, a directional change towards
higher intensities occurred and the cycle was repeated until five suprathreshold and five
subthreshold values were determined. An inflection point was calculated as the average value
of the ten suprathreshold and subthreshold to determine the MPT.

Mechanical Temporal Summation (MTS) was assessed using a single 256 mN pinprick (MRC Systems GmbH, Heidelberg, Germany) stimulus applied in triplicate to the skin surface of the selected sites, followed by a series of 10 identical stimuli (1 Hz – metronome-guided). MTS was calculated as the average pain rating from the series of 10 stimuli minus the average pain rating from the three trials with the single stimulus.

Pressure Pain Threshold (PPT)/Pressure Pain Tolerance (PPTol) was assessed using a digital, handheld pressure algometer (Algometer II, Somedic SenseLab AB, Norra Mellby, Sweden). The pressure was manually increased at a rate of 50 kPa/s (1000 kPa max) until participants indicated that the sensation of pressure became one of faint pain (PPT) and the maximum pressure pain that the participant can tolerate (PPTol), respectively. The average of 3 trials per site was used for analysis.

251 Conditioned Pain Modulation (CPM): Tonic pressure pain was used as the conditioning 252 stimulus delivered via a cuff (Hokanson, Bellevue, WA) attached to the gastrocnemius muscle of 253 the non-dominant leg. Pressure intensities were individually calibrated for each participant to 254 elicit moderate pain (pain rating at 40-60 on a scale of 100) (40, 41). PPT served as the test 255 stimulus and was measured 3 times at the dominant trapezius muscle prior to and during the 256 cuff stimulation. Pain ratings were obtained every 15 s prior to and during cuff stimulation for up 257 to 90s. CPM magnitude was calculated as patient-reported pain ratings during conditioned cuff 258 pressure stimuli.

260

Only QST results on the standard sites (forearm, trapezius) were used for correlation analysis as each SCD participant often had different primary painful site(s).

261

262 Multiplex immunoassays and enzyme-linked immunosorbent assay (ELISA)

263 Plasma concentrations of 80 inflammatory human cytokines, chemokines, growth factors, 264 soluble receptors, and effector molecules and 18 human autoantibodies were simultaneously 265 measured using the Immune Response 80-Plex Human ProcartaPlex™ Panel (Cat. #: EPX800-266 10080-901, Invitrogen, Carlsbad, CA) and the MILLIPLEX MAP Human Autoimmune 267 Autoantibody Panel (HAIAB-10K, MilliporeSigma, Burlington, MA), respectively, according to the 268 manufacturer's instructions. The beads were read on a BioPlex 200 system (Bio-Rad, Hercules, 269 CA). The standards at 4-fold serial dilutions were run on each plate in duplicate and used to 270 calculate the concentrations of human cytokines, chemokines, growth factors, soluble receptors, 271 and effector molecules using the Bio-Plex Manager Software (Bio-Rad, Hercules, CA) as 272 previously reported (42). Plasma samples were diluted 100-fold for the autoantibody multiplex 273 assay, and the levels of the autoantibodies were reported as mean fluorescence intensity (MFI) 274 after background MFI subtraction. The plasma levels of C-reactive protein (CRP) were 275 quantified using human CRP Duoset ELISA Kit (R&D Systems, Minneapolis, MN) according to 276 the manufacturer's instructions.

277

Flow cytometry

Freshly prepared PBMCs were stained with fluorochrome-conjugated antibodies against human CD45, CD71 (expressed on erythroid precursors), BCAM, and CD235ab (also known as GPA: glycophorin A, the major sialoglycoprotein on RBCs and their precursors) to measure the

aggregation between RBC/erythroid precursors and CD45⁺ leukocytes. Cells stained with
surface markers were acquired using a BD LSRFortessa flow cytometer (BD Biosciences, San
Jose, CA). Flow data were analyzed using FlowJo v10 software (Tree Star, San Carlos, CA).
The percentage of CD235ab^{hi} cells among the CD45⁺ leukocytes was defined as the
RBC/reticulocyte-leukocyte aggregation rate. The association of RBCs/reticulocytes with
lymphocytes or monocytes were determined based on their characteristics of FSC and SSC on
flow cytometry, respectively.

289

290 Statistical analysis

291 Statistical analysis was performed using GraphPad Prism 10 and SPSS 29. Data were 292 expressed as median and interquartile range (Tables 1-3). Differences between 2 groups were 293 calculated using the Mann-Whitney test for continuous variables (Tables 1-2). x2 test was used 294 for comparison between 2 groups for gender distribution (Table 1). Adjusted p values were 295 calculated for the 80-plex and 18-plex analytes using the Holm-Sídák correction for multiple 296 comparisons (Table 3). Inflammatory mediators that were heightened in the SCD participants 297 were used for subsequent Spearman correlation analyses using age, gender and SCD 298 genotype as covariables (Tables 4-6). p < 0.05 was considered statistically significant. p < 0.06299 was considered a clear trend toward significance.

300

301 Results

302 Characteristics of the study cohort: demographics, laboratory exams, patient reported

303 outcomes and sensory sensitivity

304 Demographics and clinical characteristics of participants are summarized in Table 1. SCD 305 participants and HCs showed no significant differences in terms of age and gender distribution. 306 Compared to the HCs, SCD participants exhibited higher numbers of white blood cells (WBCs), 307 reticulocytes, platelets, neutrophils, monocytes, and basophils but reduced RBCs, hemoglobin, 308 and hematocrit (HCT). Additionally, SCD participants displayed elevated levels of mean 309 corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), red cell distribution width 310 (RDW), and the systemic inflammation marker CRP than HCs (Table 1). The differences in the 311 absolute numbers of lymphocytes and eosinophils approached a clear trend toward significance 312 (p < 0.06) between the two groups (Table 1). 313 As indicated in Table 2, SCD participants reported increased pain interference and 314 intensity, more painful body sites, reduced physical functioning, and higher levels of depression 315 relative to HCs. Compared to HCs, SCD participants also displayed hypersensitivity to 316 experimental mechanical (MDT, MTP, MTS), cold (CPT), and pressure stimuli (PPT and PPTol),

but not hot stimuli (HDT, HPT) as measured by QST (Table 2).

318

319 SCD participants presented with elevated proinflammatory cytokines, chemokines,

320 growth factors, effector molecules, and soluble receptors compared to HCs

321 SCD participants had significantly higher plasma levels of 35 analytes compared to HCs 322 (Table 3). These elevated analytes encompassed 10 chemokines (CCL21, CCL23, Eotaxin-2, 323 Gal-3, GRO- α , IP-10, MCP-2, MIP-1 α , MIP-1 β , and MIP-3 α), 2 effector molecules (granzymes A 324 and B), 9 growth factors (BAFF, bNGF, G-CSF, GM-CSF, HGF, IL-7, IL-20, IL-34, and LIF), 8 325 pro-inflammatory cytokines (IFN-γ, IL-1α, IL-2, IL-8, IL-9, IL-18, TNF-α, and TNF-β), 4 type II 326 inflammatory/anti-inflammatory cytokines (IL-4, IL-5, IL-6, and TSLP), and 2 immune modulating 327 soluble receptors (PTX3 and TREM-1) (Table 3 and Supplementary Table 1). In addition, levels 328 of the endothelial cell growth factor VEGF-A and the proinflammatory cytokine IL-17A trended

329	higher in the SCD participants ($p < 0.06$) (Table 3 and Supplementary Table 1). After being
330	corrected for multiple comparisons, 9 out of the 37 altered analytes remained significantly higher
331	in the SCD participants compared to the HCs. These included 4 chemokines (CCL23, Gal-3, IP-
332	10, and MCP-2), 2 growth factors (HGF and IL-34), 2 proinflammatory cytokines (IFN-g and IL-
333	18), and the soluble receptor PTX3 (Table 3 and Supplementary Table 1). Notably, among
334	these altered analytes, HGF, IL-18, IP-10, and MCP-2 exhibited the most significant
335	upregulation in SCD participants in comparison to HCs (Table 3 and Supplementary Table 2).

337 Both anti-nuclear autoantibodies (ANAs) and non-ANAs were present and elevated in

338 SCD participants

339 Plasma concentrations of autoantibodies against 18 human antigens were simultaneously 340 measured using a multiplex immunoassay. We identified the presence of autoantibodies against 341 4 human antigens, including Sjögren's Syndrome-related antigen A/Ro60 kDa (SSA/Ro60), 342 ribosomal P, myeloperoxidase (MPO), and PM/Scl-100, which were significantly elevated in 343 SCD participants when compared to HCs (Fig. 1A, 1B). After multiple comparison corrections, 344 SSA/Ro60 and MPO remained significantly higher in the SCD subjects (p = 0.048 and p =345 0.022, respectively). It is noteworthy that while SSA/Ro60 autoantibody is typically classified as 346 an ANA, autoantibodies against the ribosomal P, MPO, or PM/Scl-100 are not categorized as 347 ANAs (non-ANAs). Thus, both ANAs and non-ANAs in the bloodstream were significantly 348 elevated in SCD participants compared to HCs.

349

350 SCD participants exhibited abnormally high rates of RBC/reticulocyte-leukocyte

351 aggregation

352 RBC/reticulocyte-leukocyte aggregates in SCD participants were assessed using flow 353 cytometry (Fig. 2A). Freshly isolated PBMCs were stained with antibodies again human CD45 354 (a marker expressed on all leucocytes), CD235ab (a marker expressed on RBCs and their 355 precursors), BCAM, and CD71 (transferring receptor-1, a specific marker of reticulocytes 356 among the RBC population). As depicted in Fig. 2B, the percentage of total CD235ab^{hi}CD45⁺ 357 aggregates were significantly higher in SCD participants compared to HCs. The percentage of 358 CD71⁺ reticulocyte aggregates was significantly higher in SCD participants compared to HCs 359 (Fig. 2C, left panel). In parallel, the percentage of CD71⁺ reticulocytes in free fraction were 360 also significantly higher in SCD participants compared to HCs, indicating an increase of 361 reticulocytes in SCD participants (Fig. 2C, right panel). Similarly, BCAM expression on 362 aggregates or unaggregated RBCs was significantly higher in SCD participants compared to 363 HCs (Fig. 2D). This observation suggested that StSt PBMC samples contained higher numbers 364 of RBCs or RBC precursors, such as reticulocytes, and higher levels of the cell adhesion 365 molecule BCAM, thus contributing to the increased occurrence of aggregates. Compared to 366 HCs, the percentage of CD45⁺ lymphocytes in the aggregates were significantly lower in SCD 367 participants, whereas the frequency of monocytes was higher (Fig. 2E). When the immune cell 368 types in PBMCs and the aggregates in the SCD participants were analyzed and compared, 369 monocytes were enriched within the aggregates with a corresponding decrease of 370 lymphocytes within aggregation relative to PBMCs (Fig. 2F), indicating RBCs/RBC 371 precursors preferentially interacted with monocytes within the aggregates.

372

373 Comprehensive analysis revealed correlations of inflammatory mediators with

374 autoantibodies and RBC/reticulocyte-leukocyte aggregation in SCD participants

375 Next, we evaluated correlations between the 37 elevated inflammatory mediators (9 376 analytes with adjusted p<0.05 bolded) that were listed in Table 3, altered autoantibodies 377 targeting SSA/Ro60, ribosomal PMPO, and PM/ScI-100, and RBC/reticulocyte-leukocyte 378 aggregation in StSt participants (Table 4). The elevated plasma level of IL-4 and IL-5, both type 379 Il cytokines known for facilitating the development of B cells into antibody-producing plasma 380 cells, exhibited significant positive associations with SSA/Ro60 autoantibodies. These 381 autoantibodies are a type of ANAs commonly linked to autoimmune diseases such as SLE 382 (Table 4) (43). IL-4 also exhibited a trend towards correlation with ribosomal P and MPO 383 autoantibodies (r = 0.31, p = 0.076 for both). Additionally, SSA/Ro60 autoantibodies showed 384 associations with multiple inflammatory mediators, including the effector molecule granzyme A, 385 2 growth factors (IL-34 and VEGF-A), and 2 proinflammatory cytokines (IL-1a and IL-9). 386 Furthermore, both IL-1a and MIP-1b positively correlated with the non-ANA autoantibodies 387 against MPO. Conversely, none of the 37 elevated inflammatory mediators were found to be 388 associated with anti-PM/Scl-100 autoantibodies (data not shown). 389 We also analyzed the association of the inflammatory mediators with RBC/reticulocyte-390 leukocyte aggregation. Two chemokines (CCL23 and MIP-1a) and the growth factor HGF 391 exhibited positive associations with the percentage of RBC/reticulocyte-leukocyte aggregates 392 (Table 4). Together, our data demonstrate that inflammation is closely linked to autoimmunity 393 and RBC aggregation with leukocytes in SCD participants at the steady state.

394

395 Correlation analysis uncovered significant associations between inflammatory mediators 396 and autoantibodies with VOCs/pain/sensory sensitivity

To investigate potential underlying factors contributing to VOCs, we examined the
 relationships of the elevated 37 inflammatory mediators, 4 autoantibodies, or RBC/reticulocyte-

leukocyte aggregates with the intervals before and after VOC episodes (Table 5). After being
adjusted for age, gender, and SCD genotypes, 6 inflammatory mediators (Extaxin-2, GRO-α, IL2, IL-6, IL-17A, and LIF) showed positive correlations with the time intervals after VOCs.
Conversely, the inflammatory cytokine IL-18 and granzyme A exhibited negative associations
with the time interval before VOCs. These results suggest that specific inflammatory mediators,
namely granzyme A and IL-18, might play a crucial role in the early detection or development of
VOCs.

406 Next, we analyzed correlations of the inflammatory mediators with pain and sensory 407 sensitivity as assessed by PROMs and QST. As presented in Table 6, several inflammatory 408 mediators were associated with patient-reported pain intensity, physical function, and sensory 409 sensitivity. A group of inflammatory mediators (G-CSF, granzyme A, BAFF, IL-9, and IL-17A) 410 exhibited positive correlations with PedsQL scores. Conversely, most of the correlations 411 between inflammatory mediators and various PROMs were negative. Specifically, 19 412 inflammatory mediators (CCL23, GM-CSF, GRO-a, MCP-2, Granzyme B, BAFF, bNGF, IL-7, IL-413 20, LIF, IL-2, IL-9, IL-17A, TNF-a, TNF-b, IL-5, IL-6, TSLP, and TREM-1) displayed negative 414 associations with physical and psychological PROMs (Pain Intensity, Pain Episode, Depression 415 Score, and Physical Function Score). Notably, 16 of the 19 factors were negatively correlated 416 with the Physical Function Score, while 8 of them had negative correlations with Pain Episode 417 Frequency/Recency. Moreover, 9 out of the 19 factors (Granzyme B, IL-20, LIF, IL-2, IL-17A, 418 TNF-b, IL-5, IL-6, and TSLP) showed a positive association with the mechanical threshold (MDT 419 forearm). Two additional factors, CCL21 and IL-8, were also positively associated with the MDT 420 forearm. Five factors (Eotaxin-2, CCL21, GRO-a, MCP-2, and TREM-1) displayed positive 421 correlations with pressure threshold (PPT trapezius). Furthermore, a group of inflammatory 422 factors (Eotaxin-2, CCL21, GRO-a, MCP-2, MIP-3a, HGF, VEGF-A, IL-8, TNF-a, TNF-b, IL-5, 423 and TREM-1) displayed negative correlations with mechanical pain threshold (MPT forearm and 424 MTS forearm), and sensitivity threshold to cold (CPT forearm). Of note, several inflammatory

factors, including GRO-a, MCP-2, granzyme B, IL-2, IL-17A, TNF-b, IL-5, and TREM-1, showed
correlations with multiple measures from both PROMs and QST,

427 We also assessed the relationship of PROMs and experimental sensory sensitivity with 428 the autoantibodies and RBC/reticulocyte-leukocyte aggregations (Table 6). We found that 429 elevated autoantibodies against MPO exhibited a negative correlation with Physical Function 430 Score and strong positive correlations with PPT (trapezius) and PPTol (trapezius). However, no 431 correlations were detected between PROMS/QST and increased rate of RBC/reticulocyte-432 leukocyte aggregation, as well as BCAM and CD71 expression on the aggregates. Together, 433 our results indicate that multiple inflammatory/autoimmune markers are inversely associated 434 with the well-being of the SCD participants.

435

436 **Discussion**

This study represents an interim analysis of an ongoing clinical trial that aims at investigating the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in SCD participants (NCT05045820). Results showed that SCD participants in StSt showed higher levels of sensory sensitivity, as well as increased pain intensity, pain interference, widespread pain, physical dysfunction, and depression compared to HCs (Table 2). These results highlight the significant impact of SCD on patients' physical and emotional well-being and align with previous studies on SCD (30, 34, 38, 39, 44, 45).

We collected cross-sectional blood samples and clinical parameters to comprehensively study inflammatory mediators, autoantibody profiles, and presence of RBC/reticulocyteleukocyte aggregates, exploring their interrelations and potential relationship with VOCs, QoL, and sensory sensitivity. Specifically, we examined the plasma levels of 80 inflammatory mediators (Supplementary Table 1), the profiles of autoantibodies against 18 human antigens (Fig. 1), and the presence of RBC/reticulocyte-leukocyte aggregates in these participants (Fig.

450 2). Moreover, we investigated the correlations between these analytes and their potential
451 relationship with VOCs, QoL, and sensory sensitivity in SCD participants. By examining these
452 analytes and their relationships, we sought to identify potential mechanisms and therapeutic
453 targets for further exploration and investigation.

454 SCD is characterized by a persistent pro-inflammatory state that leads to elevated levels 455 of inflammatory mediators in the bloodstream. Inflammatory mediators are vital signaling 456 molecules that play a crucial role in the development of pain, VOCs, and the pathogenesis of 457 SCD (8, 17, 46). A recent study measured the serum levels of 27 inflammatory mediators 458 including 15 cytokines, 7 chemokines, and 5 growth factors in 27 StSt and 53 HCs (28). The 459 results revealed that significantly higher levels of several cytokines, chemokines, and growth 460 factors in SCD participants compared to HCs (28). Strikingly, SCD participants exhibited 461 elevated serum concentrations of pro-inflammatory molecules, such as IL-1β, IL-12p70, and IL-462 17A, when compared to SCD participants experiencing VOC (28). Here we expanded the 463 spectrum of analyses and observed that SCD participants exhibited higher plasma levels of 37 464 out of 80 analytes, including 13 pro-inflammatory/anti-inflammatory cytokines, 10 chemokines, 465 10 growth factors, 2 effectors, and 2 soluble receptors (Table 3 and supplementary Tables 1 466 and 2). These findings collectively indicate a pro-inflammatory bias in SCD participants as 467 compared to HCs.

468 Numerous cytokines elevated in our study, such as IL-1α, IL-4, IL-5, IL-6, IL-7, IL-8, TNF-a 469 were previously shown to involved in VOC-related acute clinical complications such as acute 470 chest syndrome, pulmonary hypertension, and pulmonary thrombosis (47-53). Systemic 471 inflammation and modulation of the immune system with crosstalk of immunological molecules 472 and immune cells were associated with the pathogenesis of persistent pain and the onset of 473 VOCs in SCD. Plasma IFN-y was augmented in steady-state SCD, which could modulate 474 macrophage function and increase T helper cell expansion in SCD and most likely reflect 475 inflammasome formation in inflammatory cells (52, 54, 55). Endothelium activation could in turn

476 produce and release a number of potent inflammatory molecules, including IL-1 α , IL-1 β , IL-6, IL-477 8, GM-CSF, MCP-1, plasminogen activator inhibitor-1, and RANTES (52, 53, 56-58). The 478 maturation and release of bioactive IL-1 β and IL-18 (59-65), two vital immunoregulatory and 479 proinflammatory cytokines, are governed by inflammatory caspases operating within specialized 480 signaling platforms referred to as inflammasomes. Elevated plasma levels of IL-1 β and IL-18 in 481 SCD participants strongly suggest an aberration in the regulation of inflammasome activation 482 within this particular group. In addition, IL-1β exerts a potent activation effect on leukocytes and 483 ECs. Meanwhile, IL-18 plays an important role in stimulating vascular smooth muscle cell 484 proliferation and migration, along with promoting the productions of IFN-y, IL-2 and IL-12. These 485 actions collectively exacerbate the inflammatory milieu in SCD participants (51, 54, 55). Notably, 486 excessive production of IL-8 and RANTES contributes to the dehydration of sickle RBC, leading 487 to an increase in RBC density and rigidity (66). This, in turn, enhances the adhesion of RBCs to 488 the endothelium (67), a phenomenon closely linked to the severity of VOCs. These findings 489 suggest that SCD participants experience persistently high levels of inflammatory mediators 490 during StSt phases, even in the absence of severe clinical symptoms like VOCs. 491 Several inflammatory mediators were associated with the presence of autoantibodies and 492 RBC/reticulocyte-leukocyte aggregation in SCD participants. Specifically, 8 inflammatory factors

autoantibodies targeting 2 human antigens (SSA/Ro60 and MPO) (Table 4). Anti-SSA/Ro60
autoantibodies are typically classified as ANAs, while anti-MPO autoantibodies are categorized
as non-ANAs. Thus, our results indicate that elevated inflammatory mediators are closely linked
to both ANAs (anti-SSA/Ro60 autoantibodies) and non-ANAs (anti-MPO autoantibodies) in the
bloodstream of SCD participants. Notably, the vast majority (7 out of 8) of inflammatory
mediators displayed positive associations with both ANA (SSA/Ro60) and non-ANAs (Table 4).
Given that mature RBCs in mammals lack nuclei, mitochondria, and other organelles (68), these

(MIP-1b, granzyme A, IL-34, VEGF-A, IL-1a, IL-9, IL-4, and IL-5) were positively associated with

493

501 inflammatory mediators are more likely to be implicated in autoimmune responses to cellular

debris from other types of cells rather than mature RBCs. This finding suggests a potential link
between ANA-associated autoimmunity and the presence of specific inflammatory mediators,
which may contribute to our understanding of autoimmune processes and their association with
certain cellular components in SCD.

506 In SCD participants, a complex and detrimental cycle is established through the interplay 507 between inflammation and the formation of RBC/reticulocyte-leukocyte aggregates (69, 70). 508 Inflammatory mediators disrupt immune responses, leading to an increased aggregation of 509 RBCs/reticulocytes with leukocytes. Consequently, these aggregates exacerbate blood vessel 510 blockages, further impeding blood flow and perpetuating the cycle of inflammation and tissue 511 damage. This process triggers the release of additional inflammatory mediators, thus fueling a 512 vicious circle of inflammation and VOCs. This vicious circle plays a significant role in the 513 pathophysiology of SCD and significantly contributes to the recurrent pain crises and organ 514 damage observed in affected individuals. We analyzed the association of inflammatory 515 mediators with RBC/reticulocyte-leukocyte aggregation. In line with previous studies, our results 516 also revealed 2 chemokines (CCL23 and MCP-1a) and 1 growth factor (HGF) that were 517 associated with the aggregation (Table 4). These results provide important insights into the 518 relationship between inflammation and RBC/reticulocyte-leukocyte aggregates that are 519 associated with the occurrence and severity of VOCs.

520 SCD participants experience sudden and intense episodes of VOCs, which are 521 challenging to predict and manage (71, 72). However, understanding of the circulating markers 522 and their pathological processes during the transitioning phase from StSt to VOC episodes is 523 extremely limited due to the unpredictable and rapid progression of the onset of VOCs. A 524 previous study identified PDGF-BB and IL-1Rα as potential indicators for the acute-to-chronic 525 stage in SCD (28). Our data revealed that 2 elevated inflammatory mediators (IL-18 and 526 granzyme A) were associated with time the intervals prior to VOC onset and 6 mediators 527 (Extaxin-2, GRO- α , IL-2, IL-6, IL-17A, and LIF) were associated with time intervals after active

528 VOCs (Table 5), suggesting that these 8 mediators hold the potential to serve as novel 529 biomarkers for predicting VOC episodes. Of particular note, IL-18 has emerged as a critical 530 proinflammatory regulator in both innate and adaptive immune responses (73), and blocking IL-531 18 has been associated with mitigating neuropathic symptoms and enhancing the analgesic 532 activity of morphine and buprenorphine (74). Inhibition of Granzyme A has been shown to 533 reduce the levels of IL-6 and TNF-a (75). Thus, our results underscore the significance of 534 specific inflammatory mediators in the early detection and development of VOCs, as well as 535 potential avenues for pain management in SCD participants experiencing VOCs.

536 The existing literature has extensively studied the inflammation- and immunity-based 537 mechanisms in SCD as compared to HCs, as well as the differences between StSt and VOC 538 phases. However, there are limited studies investigating the relationship of inflammatory 539 markers with clinical symptoms and sensory sensitivity during StSt. In the present study, we 540 found that multiple inflammatory molecules were negatively associated with pain intensity 541 (higher score indicated higher pain), the frequency/recency of clinical pain episodes (higher 542 score indicated higher frequency/recency of acute pain episodes), emotional distress 543 (depression), and physical dysfunction (higher score indicated higher physical dysfunction) in 544 SCD participants. Conversely, higher levels of several soluble factors correlated with higher 545 QoL and less pain. SCD participants with less severe Pain Episodes Score (higher score 546 indicated higher severity) were associated with higher levels of GRO-a, MCP-2, granzyme B, 547 bNGF, IL-7, IL-2, IL-17, and TREM 1 (Table 6). Of particular interest, higher IL-17A levels were 548 also correlated with less pain intensity, physical dysfunction and higher QoL (higher PedsQL 549 score indicated higher QoL). In fact, elevated IL-17A is associated with absence of acute chest 550 syndrome in SCD participants, indicating a protective role (76). Consistently, higher levels of 551 many inflammatory markers were also associated with decreased sensory sensitivity (in other 552 words: increased threshold/tolerance to experimental stimuli) in response to mechanical (MDT, 553 MPT, MTS), thermal (CPT), and pressure (PPT and PPTol) stimuli. We observed that SCD

554 participants who had higher levels of Eotaxin-2, CCL21, GRO-a, MCP-2, HGF, and TREM-1 555 simultaneously exhibited lowered cold pain sensitivity (in other words: increased tolerance of 556 cold-induced pain). These novel findings have not been reported in existing literature in SCD. 557 The underlying mechanisms of these intriguing observations are unknown and warrant future 558 investigation. We speculate that SCD participants experiencing recurrent extremely painful 559 VOCs-related episodes developed resistance and pain inhibitory effect, thus exhibited 560 decreased sensory sensitivity and increased tolerance to experimental pain stimuli, which 561 therefore inhibited the antidromic release of proinflammatory mediators at periphery. This 562 correlation profile suggested the interactive and distinct roles of inflammatory mediators in the 563 processing of pain, and sensory sensitivity at StSt, and could be utilized for more extensive 564 studies to explore the underlying nociceptive pathways in SCD.

565 In line with the correlation profile presented in Table 6, elevated anti-MPO autoantibodies 566 were associated with decreased sensitivity and tolerance to pressure pain (PPT trapezius and 567 PPTol trapezius). Notably, MPO plays a crucial role as a marker and modulator of inflammation 568 and oxidative stress, primarily originating from activated leukocytes and neutrophils (77). A 569 previous study demonstrated that increased MPO impairs EC function through vascular 570 oxidative stress, while inhibiting MPO shows promise in improving vasodilation in mouse models 571 of SCD (78). Furthermore, many SCD participants experience heightened cold sensitivity (79). 572 and exposure to potential triggers, such as cold temperatures or stress, can induce 573 vasoconstriction, potentially leading to VOC (80, 81). Therefore, elevated autoantibodies, such 574 as anti-MPO autoantibodies (Fig.1), might contribute to vasoconstriction during the prodromal 575 phase of VOCs while simultaneously interacting with immune- and inflammatory-targets (Table 576 4) to modulate pain inhibitory effect at StSt.

577 Inflammation, autoimmunity, and RBC/reticulocyte-leukocyte aggregations are believed to 578 play a significant role in the pathogenesis of pain and VOCs in SCD participants (23, 82, 83). 579 However, the direct connections of these factors with pain and VOCs in SCD participants are

580 not fully understood. Our comprehensive analyses of these cross-sectional clinical samples 581 provide valuable insights into the correlations between inflammatory mediators, autoantibody 582 profiles, RBC/reticulocyte-leukocyte aggregation, clinical lab test results, and their associations 583 with the onset of VOCs and pain sensitivity in SCD participants. This knowledge has the 584 potential to significantly contribute to the development of suitable biomarkers/endpoints for 585 clinical diagnosis of pain episodes in SCD participants, as well as targeted therapeutic 586 approaches and improved management strategies for individuals affected by this condition. 587 However, it is essential to acknowledge the limitations of our cross-sectional study, including 588 small sample size, potential bias, confounding factors, the absence of insight into temporal 589 trends, and the inability to establish causality. To address these limitations, we have undertaken 590 efforts to collect longitudinal clinical samples throughout the duration of our clinical trial cohort 591 and expand our sample size with ongoing recruitment efforts. This longitudinal approach is 592 expected to provide a stronger foundation for establishing causal relationships between the 593 analyzed variables. By observing changes over time, we can better infer cause-and-effect 594 relationships of these variables, thus advancing our understanding of the mechanisms 595 underlying the pathogenesis of SCD. Furthermore, the combination of cross-sectional and 596 longitudinal approaches will enable us to gather complementary data, extending our 597 investigations to address a broader range of clinical questions in both SCD participants and 598 SCD participants experiencing acute VOC. The information gathered from these approaches will 599 be pivotal in evaluating the clinical efficacy and neurobiological mechanisms of acupuncture 600 analgesia in SCD participants participating in our clinical trial.

601

602 Author contribution

603	W.L., Q.Y., and Y.W. supervised experimental performance and data collection, analysis,
604	and interpretation; A.Q.P., C.D., and B.R. assisted with data collection and figure preparation.
605	F.S. assisted with data analyses and figure preparation; W.L., Q.Y., and Y.W. drafted and edited
606	the manuscript; S.E.H., and R.E.H. helped with editing the manuscript; Y.W. and A.R.O.
607	directed patient recruitment; A.R.O., R.M., N.M., S.A.J., B.M.H., A.G. facilitated recruitment for
608	the study; Y.W. developed the concepts, directed overall performance and quality of the clinical
609	investigation.
610	
611	Authors Statement of Competing Interest
612	All authors have read the journal's authorship agreement and policy on disclosure of
613	potential conflicts of interest.
614	
615	Acknowledgement
616	The authors would like to thank Tyler James Barret, Nayana Dutt, Payton Mittman, Bea
617	Paras, Ramat Gbemisola Suleiman-Oba, Amy Gao and Yongqi Yu for assisting with
618	experimental performance, and clinical team staff at Indiana University Clinical Research Center
619	for patient scheduling and blood draw performance.
620	

621 Funding Support

- 622 This work was supported by NIH K99/R00 award (Grant # 4R00AT010012 to Y.W.) and
- 623 Indiana University Health Indiana University School of Medicine Strategic Research Initiative
- 624 funding to Y.W.
- 625





633 as median + upper interquartile range (IQR). **B)** Scatter plots demonstrating the plasma levels

of 4 autoantibodies (anti-SSA/Ro60, anti-Ribosomal P, anti-Myeloperoxidase, and anti-PM/Scl-100) that were significantly elevated in SCD participants compared to healthy controls. Lines represent the median. SCD, sickle cell disease; HC, healthy control. Mann-Whitney test was used to compare the results from SCD patient versus HC samples. *p < 0.05; **p < 0.01.





640 Fig. 2. Comparison of RBC/reticulocyte aggregation with CD45⁺ PBMCs in SCD

641 participants versus healthy controls. Freshly isolated peripheral blood mononuclear cells
642 (PBMCs) from the SCD participants (n=12) and healthy controls (HC, n=17) were analyzed for

643 RBC/reticulocyte aggregation with CD45⁺ PBMCs by flow cytometry. **A)** Gating strategies for

644 flow cytometric analysis of RBC/reticulocyte-CD45⁺ leukocytes aggregation. PBMCs were 645 stained with fluorochrome-conjugated antibodies against human CD45, CD235ab, CD71, BCAM 646 and isotype control antibodies. CD235ab⁺ cells that were not associated with CD45⁺ PBMCs 647 were defined as RBC/reticulocyte in free fraction (RBC). Within the CD45⁺ cells, CD235ab^{hi} cells 648 were defined as the RBC/reticulocyte-CD45⁺ leukocyte aggregates. The gate for CD71⁺ 649 RBC/reticulocyte and RBC/reticulocyte-leukocyte aggregates were based on the isotype control. 650 BCAM level was expressed as mean fluorescent intensity (MFI). Lymphocytes (LYM) and 651 monocytes (MC) were gated based on their FCS and SSC chrematistics. B) Scatter plots 652 showing a significantly higher percentage of RBC/reticulocyte-CD45⁺ leukocyte aggregation in 653 the SCD participants than HC. C, D) Scatter plots displaying higher levels of CD71⁺ erythroid 654 precursors (C) and the cell adhesion molecule BCAM (D) on both aggregated and 655 unaggregated RBC/reticulocyte in the SCD participants compared to HC. E) Scatter plots 656 comparing the frequencies of lymphocytes and monocytes within RBC/reticulocyte-CD45⁺ 657 leukocyte aggregates. F) Before and after plots showing the percentages of lymphocytes (left) 658 were reduced while those of monocytes (right) were heightened in the aggregates compared to 659 PBMCs in the SCD subjects. Mann-Whitney test was used to compare the results from SCD 660 patient versus HC samples. Wilcoxon test was used to calculate the differences between 661 aggregates and PBMCs. *p < 0.05; **p < 0.01; ***p < 0.001. 662 663 664 665 666 667

Parameters	HCs (n=23)	SCD (n=40)	<i>p</i> value
Demographics			
Age (years)	38 (22-57)	34 (23-41)	0.16
Gender (% females)	13 (57%)	23 (58%)	0.94
SS/Sβ0/SC/Sβ+ thalassemia (n/n/n/n)	N/A	23/3/11/3	
Hemogram/Platelets/WBC Differential			
WBC (k/cumm)	5.1 (4.0-6.3)	8.8 (6.1-11.4)	0.0001
RBC (million/cumm)	4.6 (4.3-5.1)	2.9 (2.4-3.7)	<0.0001
Hgb (GM/dL)	13.0 (12.2-14.3)	10.2 (8.0-11.6)	<0.0001
HCT (%)	38.8 (36.4-41.9)	29.2 (23.6-34.0)	<0.0001
Absolute Retic Number (k/cumm)	48.8 (41.6-71.0)	131.2 (88.5-216.4)	<0.0001
Hemoglobin A (%)	97.4 (88.5-97.6)	23.0 (13.8-30.6)	<0.0001
Hemoglobin S (%)		63.4 (49.1-73.1)	
Hemoglobin F (%)		5.8 (2.4-13.4)	
MCV (fL) [81-99]	86 (81-89)	94 (83-104)	0.020
MCH (pg) [27.0-34.0]	28.4 (27.3-29.6)	32.3 (27.5-35.8)	0.0033
RDW (%) [11.5-14.5]	13.7 (13.3-14.9)	18.4 (15.8-23.6)	<0.0001
Platelet (k/cumm) [150-450]	246 (231-270)	309 (247-424)	0.0029
Absolute Neutrophil	2.75 (1.6-3.8)	4.8 (3.1-7.2)	0.0005
Absolute Lymphocyte	2.1 (1.5-2.5)	2.4 (1.7-4.1)	0.055#
Absolute Monocyte	0.4 (0.3-0.4)	0.8 (0.5-1.1)	<0.0001
Absolute Eosinophil	0.1 (0.1-0.2)	0.2 (0.1-0.4)	0.058#
Absolute Basophil	0 (0-0)	0.1 (0-0.1)	0.0007
Immunological tests			
C-reactive protein (mg/ml)	1.1 (0.4-2.7)	3.9 (1.6-7.3)	0.0038
Note: HCs, healthy controls; SCD, sic	kle cell disease; WB	C, white blood cell; RE	BC, red bloc

Table 1.	Clinical and	hematological	characteristics	of the	study	particip	pants
----------	---------------------	---------------	-----------------	--------	-------	----------	-------

669 **Note:** HCs, healthy controls; SCD, sickle cell disease; WBC, white blood cell; RBC, red blood 670 cell; Hgb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean 671 corpuscular hemoglobin; RDW, red cell distribution width. The Mann-Whitney test was used to 672 compare differences between patients with SCD and healthy controls (HC) for continuous 673 variables. χ^2 test was used for comparison of gender distribution between the 2 groups. *p* < 674 0.05 was considered significant. [#]*p* < 0.06 was considered as a clear trend toward significance. 675

Parameters	HCs (n=23)	SCD (n=33)	p value
PROMs			
PainDetect_Total score	7 (7-7)	19 (14-24)	<0.0001
BPI_Pain Interference Score	0 (0-0)	4.2 (1.8-5.6)	<0.0001
FPS_Widespread Pain Index	0 (0-0)	6 (3-8)	<0.0001
PROMISE 29_Physical Function Score	4 (4-4)	7 (5-11.5)	<0.0001
PROMISE 29_Pain Intensity Score	0 (0-0)	5 (4-6)	<0.0001
HADS_Depression Score	1 (0-3)	4.5 (2.0-7.8)	0.0002
Pain Episode Frequency Score	N/A	8 (6-9)	
Number of VOCs in preceding 12 months	N/A	4 (2-7)	
PedsQL_Total Score	N/A	52 (43-63)	
Quantitative Sensory Testing			
MDT (forearm)	0.4 (0.2-0.5)	0.3 (0.1-0.5)	0.0433
MDT (primary site)	0.3 (0.2-0.5)	0.2 (0.1-0.6)	0.4946
MPT (forearm)	77.0 (40.0-105.7)	62.4 (23.2-128.0)	0.6220
MPT (primary site)	83 (45.8-161.7)	41.6 (15.3-104.0)	0.0444
MTS (forearm)	6.7 (0.0-29.2)	8.7 (3.3-23.3)	0.3783
MTS (primary site)	5.0 (1.5-18.8)	15.3 (5.3-23.0)	0.0434
CDT (forearm)	-2.4 ((-4.3)-(-1.6))	-2.0 ((-3.1)-(-1.5))	0.3888
CDT (primary site)	-2.0 ((-3.4)-(-1.4))	-2.4 ((-3.5)-(-1.5))	0.5940
CPT (forearm)	-13.3 ((-24.6)-(-5.4))	-6.8 ((-13.1)-(-3.9))	0.0276
CPT (primary site)	-15.65 ((-26.5)-(-6))	-7.3 ((-12.7)-(-4.3))	0.0274
HDT (forearm)	3.3 (2.5-4.0)	3.6 (2.5-4.4)	0.8099
HDT (primary site)	3.6 (3.1-5.9)	4.1 (2.7-5.7)	0.6730
HPT (forearm)	7.8 (4.8-11.1)	8.7 (5.4-10.7)	0.9278
HPT (primary site)	7.3 (6.2-10.9)	8.3 (6.1-10.3)	0.8623
PPT (trapezius)	255.5 (179.3-364.5)	203.5 (164.0-278.5)	0.0404
PPT (primary site)	321.0 (196.0-539.0)	192.0 (142.0-263.8)	0.0026
PPTol (trapezius)	415.5 (341.8.5-559.6)	316.5 (2250-391.8)	0.0129
PPTol (primary site)	526.0 (316.0-827.0)	302.0 (223.8-463.8)	0.0029
CPM (pain rating)	43.0 (30.0-54.0)	39.0 (28.0-51.0)	0.7441

Table 2. Patient-reported outcome measures and quantitative sensory testing

677Note: HCs, healthy controls; SCD, sickle cell disease; MDT, mechanical detection threshold;678MPT, mechanical pain threshold; MTS, mechanical temporal summation; Mechanical CDT, cold679detection threshold; CPT, cold pain threshold; HDT, heat detection threshold; HPT, heat pain680threshold; PPT, pressure pain threshold; PPTol, pressure pain tolerance; CPM, conditioned pain681modulation. The Mann-Whitney test was used to compare differences between patients with682SCD and HCs. p < 0.05 was considered significant.

Categories	Analytes	HCs (n=18)	SCD (n=36)	p	Adjusted <i>p</i>
	CCL21	0.1 (0-12.8)	20.4 (0.6-71.5)	0.00280	0.17337
	CCL23	487 (302-639)	874 (574-1285)	0.00014	0.01046
	Eotaxin-2	0.1 (0-6.6)	10.4 (0-97.7)	0.04479	0.88393
	Gal-3	6749 (4949-8982)	15144 (6910-34355)	0.00055	0.03958
Chamakinas	GRO-α	1.7 (1.3-2.0)	2.4 (1.7-3.1)	0.00625	0.33050
Glielilokilles	IP-10	17.2 (10.1-25.6)	36.9 (21.3-60.7)	0.00012	0.00891
	MCP-2	0.2 (0.1-0.7)	2.1 (0.7-5.3)	0.00001	0.00091
	MIP-1α	0 (0-1.6)	2.7 (0.7-6.9)	0.00629	0.33050
	MIP-1β	30.0 (14.9-40.5)	56.8 (29.7-71.5)	0.00134	0.09067
	MIP-3α	5.1 (4.4-5.5)	5.9 (5.5-7.6)	0.00196	0.12821
Effectors	Granzyme A	3.4 (0-10.9)	11.1 (4.6-23.5)	0.00442	0.25324
LITECTORS	Granzyme B	10.4 (7.0-28.0)	20.2 (12.6-31.9)	0.01758	0.62295
	BAFF	3.053 (1.051-4.074)	4.283 (2.555-6.08)	0.01758	0.62295
	bNGF	1.1 (0.9-3.1)	2.1 (1.2-4.6)	0.02762	0.75348
	G-CSF	4.2 (0-89.4)	50.7 (25.3-116.3)	0.01299	0.51903
	GM-CSF	0 (0-0)	3.8 (0-20.5)	0.00256	0.16236
Growth	HGF	6.4 (2.9-20.3)	56.2 (13.1-70.2)	0.00003	0.00253
factors	IL-7	0 (0-0)	0 (0-1.1)	0.02305	0.70251
	IL-20	6.9 (5.5-10.5)	9.6 (6.7-21.8)	0.02509	0.72631
	IL-34	11.5 (8.3-18.5)	21.9 (13.7-43.9)	0.00051	0.03716
	LIF	0.6 (0.4-2.7)	2.4 (1.1-4.8)	0.00991	0.44448
	VEGF-A	50.02 (33.59-65.04)	73.17 (35.73-156.1)	0.0523#	0.91076
	IFN-γ	1.8 (1.4-2.2)	3.9 (2.3-4.8)	0.00023	0.01737
	IL-1α	3.9 (2.5-11.0)	6.9 (4.1-16.4)	0.04832	0.89752
	IL-2	4.3 (3.2-6.2)	9.1 (4.5-14.7)	0.00940	0.43242
Inflammatory	IL-8	0.7 (0.1-6.9)	5.5 (2.1-10.2)	0.01183	0.49255
cvtokines	IL-9	0.2 (0-1.4)	1.4 (0.5-3.0)	0.01134	0.48383
oytoninoo	IL-17A	0 (0-1.725)	0.98 (0-3.959)	0.05482#	0.91633
	IL-18	5.0 (3.4-7.1)	13.7 (7.2-50.8)	0.00002	0.00173
	TNF-α	2.2 (1.9-2.6)	2.7 (2.3-3.2)	0.00460	0.25884
	TNF-β	0.1 (0-2.2)	1.5 (0.4-4.8)	0.02021	0.66116
	IL-4	19.4 (11.2-35.1)	37.3 (18.5-77.2)	0.00901	0.42436
inflammatory	IL-5	0 (0-0.2)	3.5 (0-12.3)	0.00290	0.17675
cvtokines	IL-6	0 (0-0.8)	1.5 (0-7.4)	0.03843	0.84757
.,	TSLP	1.3 (0.8-2.2)	2.3 (1.7-3.4)	0.00791	0.38881
Soluble	PTX3	1137 (798-1924)	3045 (1557-5283)	0.00064	0.04533
receptors	TREM-1	0 (0-235.4)	248.2 (16.3-761.1)	0.02832	0.75524

 Table 3: Upregulated inflammatory mediators in SCD subjects as detected by 80plex immunoassay

684 **Note**: HCs, healthy controls; SCD, sickle cell disease. The Mann-Whitney test was used 685 to compare differences between patients with SCD and healthy controls (HC) without 686 and with Holm-Šídák correction for multiple comparisons. p < 0.05 was considered 687 cignificant. #p < 0.06 was considered a clear trend toward cignificance

687 significant. p < 0.06 was considered a clear trend toward significance.

		Auto	antibodies	Aggregation
Categories	Analytes	SSA/Ro60	Myeloperoxidase	% 692
Chemokines	CCL23 ^{&} MIP-1α			0.88* 0.88*
onemokines	MIP-1β		0.37*	0.00
Effector	Granzyme A	0.34#		697
Growth factors	HGF ^{&} IL-34 ^{&} VEGF-A	0.48** 0.33#		0.89*
Proinflammatory cytokines	IL-1α IL-9	0.35* 0.36*	0.39*	701 702
Type II cytokines	IL-4 IL-5	0.48** 0.33#		

Table 4. Correlations of upregulated inflammatory mediators with $\frac{689}{altered}$ autoantibodies and RBC/reticulocyte-leukocyte aggregation

706Note: Aggregation, RBC/reticulocyte-leukocyte aggregation. Spearman correlation707analyses were performed including age, gender and SCD genotype as covariables. *p <7080.05; ** p < 0.01, *** p < 0.001, #p < 0.06, a clear trend toward significance, *mediators709with adjusted p < 0.05 in Table 3.

711

710

Table 5: Correlations of altered inflammatory mediators with time interval from VOC crisis

			Days b	efore crisis				
	Eotaxin-2	GRO-α	IL-2	IL-6	IL-17A	LIF	IL-18 ^{&}	Granzyme A
r	0.36	0.47	0.37	0.38	0.39	0.48	-0.41	-0.43
р	0.058	0.010	0.051	0.044	0.035	0.008	0.028	0.022

712 **Note**: VOC, vaso-occlusive. The linear relationship between two variables was calculated using 713 the Spearman correlation test with age, gender, and SCD genotype as covariables, which 714 generated coefficient values (*r*) and statistical significance levels (*p*). *p* < 0.05 was considered 715 significant, *p* < 0.06, a clear trend toward significance, [&]mediators with adjusted p < 0.05 in

716 Table 3.

717

	Patient-Reported Outcomes Qua					Patient-Reported Outcomes				Sensory T	esting	
Categories	Biomarkers	Pain Intensity	Pain Episode	Depression Score	Physical Function Score	PedsQL	MDT (forearm)	MPT (forearm)	MTS (forearm)	CPT (forearm)	PPT (trapezius)	PPTol (trapezius)
Chemokines	Eotaxin-2 CCL21 CCL23 ^{&} G-CSF GM-CSF GRO- α IP-10 ^{&} MIP-1 α MIP-1 α MIP-1 β MIP-3 α		-0.50** -0.41*	-0.46*	-0.37* -0.43*	0.47*	0.41*	0.45*	-0.46* -0.51* -0.39#	-0.51* -0.60** -0.56** -0.42*	0.57** 0.49* 0.49* 0.43*	
Effectors	Granzyme A Granzyme B		-0.37*		-0.51**	0.36*	0.51*		-0.44			
Growth factors	BAFF bNGF HGF ^{&} IL-7 IL-20 LIF VEGF-A		-0.40* -0.46*	-0.46*	-0.44* -0.48** -0.35# -0.45*	0.37*	0.42* 0.43*		-0.44*	-0.43*		
Pro- inflammatory cytokines	IL-2 IL-8 IL-9 IL-17A TNF-α TNF-β	-0.37*	-0.43* -0.53**		-0.40* -0.36# -0.54** -0.42* -0.41*	0.37* 0.43*	0.44* 0.42* 0.46* 0.49*	-0.47*	-0.42* -0.44*			
Type II cytokines	IL-5 IL-6 TSLP				-0.43* -0.47* -0.53**		0.44* 0.43* 0.49*	-0.39#				
Soluble R	TREM-1		-0.42*		-0.39*					-0.45*	0.53**	
AutoAb	MPO				-0.37*						0.49**	0.44*

Table 6. Correlations of upregulated soluble factors/autoantibody with PROMs/Sensory sensitivity in SCD subjects

719 **Note:** PROMs, patient-reported outcome measures; Pain Episode, Pain Episode

720 Frequency/Recency; MDT, mechanical detection threshold; MPT, mechanical pain

threshold; MTS, mechanical temporal summation; CPT, cold pain threshold; PPT,

722 pressure pain threshold; PPTol, pressure pain tolerance; Soluble R, soluble receptor;

AutoAb, autoantibody; MPO, myeloperoxidase. Spearman correlation analyses were

performed including age, gender and SCD genotype as covariables. *p < 0.05; ** p < 0.05;

0.01, *** p < 0.00, p < 0.06, a clear trend toward significance, [&]mediators with adjusted 725 726 p < 0.05 shown in Table 3. 727 728 References 729 R. E. Ware, M. de Montalembert, L. Tshilolo, M. R. Abboud, Sickle cell disease. Lancet 1. 730 **390**, 311-323 (2017). 731 2. D. C. Rees, T. N. Williams, M. T. Gladwin, Sickle-cell disease. Lancet 376, 2018-2031 732 (2010). 733 3. O. O. Ilesanmi, Pathological basis of symptoms and crises in sickle cell disorder: 734 implications for counseling and psychotherapy. Hematol Rep 2, e2 (2010). 735 4. E. M. Novelli, M. T. Gladwin, Crises in Sickle Cell Disease. Chest 149, 1082-1093 736 (2016). 737 D. S. Darbari, V. A. Sheehan, S. K. Ballas, The vaso-occlusive pain crisis in sickle cell 5. 738 disease: Definition, pathophysiology, and management. Eur J Haematol 105, 237-246 739 (2020). 740 6. K. Takaoka, A. C. Cyril, S. Jinesh, R. Radhakrishnan, Mechanisms of pain in sickle cell 741 disease. Br J Pain 15, 213-220 (2021). 742 7. H. Tran, M. Gupta, K. Gupta, Targeting novel mechanisms of pain in sickle cell disease. 743 Hematology Am Soc Hematol Educ Program 2017, 546-555 (2017). 744 8. S. K. Ballas, K. Gupta, P. Adams-Graves, Sickle cell pain: a critical reappraisal. Blood 745 120, 3647-3656 (2012). 746 9. V. Chaar et al., Aggregation of mononuclear and red blood cells through an 747 alpha4beta1-Lu/basal cell adhesion molecule interaction in sickle cell disease. 748 Haematologica 95, 1841-1848 (2010). 749 10. B. E. Gee, O. S. Platt, Sickle reticulocytes adhere to VCAM-1. Blood 85, 268-274 (1995).

- C. C. Joneckis, R. L. Ackley, E. P. Orringer, E. A. Wayner, L. V. Parise, Integrin alpha 4
 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle
 cell anemia. *Blood* 82, 3548-3555 (1993).
- 12. J. E. Brittain, J. Han, K. I. Ataga, E. P. Orringer, L. V. Parise, Mechanism of CD47-
- induced alpha4beta1 integrin activation and adhesion in sickle reticulocytes. *J Biol Chem* **279**, 42393-42402 (2004).
- 75613.A. Kumar, J. R. Eckmam, R. A. Swerlick, T. M. Wick, Phorbol ester stimulation increases757sickle erythrocyte adherence to endothelium: a novel pathway involving alpha 4 beta 1
- integrin receptors on sickle reticulocytes and fibronectin. *Blood* **88**, 4348-4358 (1996).
- M. Udani *et al.*, Basal cell adhesion molecule/lutheran protein. The receptor critical for
 sickle cell adhesion to laminin. *J Clin Invest* **101**, 2550-2558 (1998).
- W. El Nemer *et al.*, The Lutheran blood group glycoproteins, the erythroid receptors for
 laminin, are adhesion molecules. *J Biol Chem* 273, 16686-16693 (1998).
- 763 16. R. P. Hebbel, Adhesive interactions of sickle erythrocytes with endothelium. *J Clin Invest*764 **100**, S83-86 (1997).
- 765 17. N. Conran, J. D. Belcher, Inflammation in sickle cell disease. *Clin Hemorheol Microcirc*766 68, 263-299 (2018).
- H. Elmariah *et al.*, Factors associated with survival in a contemporary adult sickle cell
 disease cohort. *Am J Hematol* **89**, 530-535 (2014).
- 19. A. Turhan, L. A. Weiss, N. Mohandas, B. S. Coller, P. S. Frenette, Primary role for
- adherent leukocytes in sickle cell vascular occlusion: a new paradigm. *Proc Natl Acad Sci U S A* 99, 3047-3051 (2002).
- T. C. Hofstra, V. K. Kalra, H. J. Meiselman, T. D. Coates, Sickle erythrocytes adhere to
 polymorphonuclear neutrophils and activate the neutrophil respiratory burst. *Blood* 87,
 4440-4447 (1996).

775	21.	R. Zennadi, A. Chien, K. Xu, M. Batchvarova, M. J. Telen, Sickle red cells induce
776		adhesion of lymphocytes and monocytes to endothelium. <i>Blood</i> 112 , 3474-3483 (2008).
777	22.	J. E. Brittain, C. M. Knoll, K. I. Ataga, E. P. Orringer, L. V. Parise, Fibronectin bridges
778		monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol 141, 872-881
779		(2008).
780	23.	S. Allali, T. T. Maciel, O. Hermine, M. de Montalembert, Innate immune cells, major
781		protagonists of sickle cell disease pathophysiology. <i>Haematologica</i> 105 , 273-283 (2020).
782	24.	R. Sesti-Costa et al., Inflammatory Dendritic Cells Contribute to Regulate the Immune
783		Response in Sickle Cell Disease. Front Immunol 11, 617962 (2020).
784	25.	O. A. Adisa et al., Association between plasma free haem and incidence of vaso-
785		occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J
786		<i>Haematol</i> 162 , 702-705 (2013).
787	26.	H. H. Al-Habboubi et al., The relation of vascular endothelial growth factor (VEGF) gene
788		polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease.
789		<i>Eur J Haematol</i> 89 , 403-409 (2012).
790	27.	N. A. Redha, N. Mahdi, H. H. Al-Habboubi, W. Y. Almawi, Impact of VEGFA -583C > T
791		polymorphism on serum VEGF levels and the susceptibility to acute chest syndrome in
792		pediatric patients with sickle cell disease. Pediatr Blood Cancer 61, 2310-2312 (2014).
793	28.	A. L. Silva-Junior et al., Immunological Hallmarks of Inflammatory Status in Vaso-
794		Occlusive Crisis of Sickle Cell Anemia Patients. Front Immunol 12, 559925 (2021).
795	29.	S. Curtis, A. M. Brandow, Responsiveness of Patient-Reported Outcome Measurement
796		Information System (PROMIS) pain domains and disease-specific patient-reported
797		outcome measures in children and adults with sickle cell disease. Hematology Am Soc
798		<i>Hematol Educ Program</i> 2017 , 542-545 (2017).
799	30.	A. M. Brandow, R. A. Farley, J. A. Panepinto, Neuropathic pain in patients with sickle
800		cell disease. Pediatr Blood Cancer 61, 512-517 (2014).

- 801 31. R. Freynhagen, R. Baron, U. Gockel, T. R. Tolle, painDETECT: a new screening
- questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 22, 1911-1920 (2006).
- 804 32. D. J. Clauw, Fibromyalgia: a clinical review. *JAMA* **311**, 1547-1555 (2014).
- 33. J. Dudeney, E. F. Law, A. Meyyappan, T. M. Palermo, J. A. Rabbitts, Evaluating the
- 806 psychometric properties of the Widespread Pain Index and the Symptom Severity scale
- in youth with painful conditions. *Can J Pain* **3**, 137-147 (2019).
- 808 34. C. M. Campbell *et al.*, An Evaluation of Central Sensitization in Patients With Sickle Cell
 809 Disease. *J Pain* **17**, 617-627 (2016).
- 35. J. A. Panepinto *et al.*, PedsQL sickle cell disease module: feasibility, reliability, and
 validity. *Pediatr Blood Cancer* **60**, 1338-1344 (2013).
- 812 36. D. S. Darbari *et al.*, Frequency of Hospitalizations for Pain and Association With Altered
 813 Brain Network Connectivity in Sickle Cell Disease. *J Pain* **16**, 1077-1086 (2015).
- 814 37. Y. Wang *et al.*, Alteration of grey matter volume is associated with pain and quality of life
 815 in children with sickle cell disease. *Transl Res* 240, 17-25 (2022).
- 816 38. R. E. Miller *et al.*, Quantitative sensory testing in children with sickle cell disease:
- additional insights and future possibilities. *Br J Haematol* **185**, 925-934 (2019).
- 818 39. D. S. Darbari *et al.*, Central sensitization associated with low fetal hemoglobin levels in
 819 adults with sickle cell anemia. *Scand J Pain* **17**, 279-286 (2017).
- 40. H. Nahman-Averbuch *et al.*, The role of stimulation parameters on the conditioned pain
 modulation response. *Scand J Pain* 4, 10-14 (2013).
- K. J. Schoen *et al.*, A novel paradigm to evaluate conditioned pain modulation in
 fibromyalgia. *J Pain Res* 9, 711-719 (2016).
- 42. F. Syed *et al.*, Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial
- 825 Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-
- 826 19. *J Infect Dis* **224**, 60-69 (2021).

827	43.	R. Yoshimi, A. Ueda, K. Ozato, Y. Ishigatsubo, Clinical and pathological roles of Ro/SSA
828		autoantibody system. Clin Dev Immunol 2012, 606195 (2012).
829	44.	S. K. Reader et al., Systematic Review: Pain and Emotional Functioning in Pediatric
830		Sickle Cell Disease. J Clin Psychol Med Settings 27, 343-365 (2020).
831	45.	V. Sagi, A. Mittal, H. Tran, K. Gupta, Pain in sickle cell disease: current and potential
832		translational therapies. Transl Res 234, 141-158 (2021).
833	46.	A. E. Alagbe, I. F. Domingos, A. D. Adekile, M. Blotta, M. N. N. Santos, Anti-
834		inflammatory cytokines in sickle cell disease. Mol Biol Rep 49, 2433-2442 (2022).
835	47.	A. Driss et al., Elevated IL-1alpha and CXCL10 serum levels occur in patients with
836		homozygous sickle cell disease and a history of acute splenic sequestration. Dis
837		<i>Markers</i> 32 , 295-300 (2012).
838	48.	R. B. Francis, Jr., L. J. Haywood, Elevated immunoreactive tumor necrosis factor and
839		interleukin-1 in sickle cell disease. J Natl Med Assoc 84, 611-615 (1992).
840	49.	O. T. Gbotosho, J. Gollamudi, H. I. Hyacinth, The Role of Inflammation in The Cellular
841		and Molecular Mechanisms of Cardiopulmonary Complications of Sickle Cell Disease.
842		<i>Biomolecules</i> 13 (2023).
843	50.	B. Keikhaei et al., Altered levels of pro-inflammatory cytokines in sickle cell disease
844		patients during vaso-occlusive crises and the steady state condition. Eur Cytokine Netw
845		24 , 45-52 (2013).
846	51.	M. H. Qari, U. Dier, S. A. Mousa, Biomarkers of inflammation, growth factor, and
847		coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost 18,
848		195-200 (2012).
849	52.	A. Pathare et al., Cytokine profile of sickle cell disease in Oman. Am J Hematol 77, 323-
850		328 (2004).

- 53. T. M. Sakamoto *et al.*, Increased adhesive and inflammatory properties in blood
- 852 outgrowth endothelial cells from sickle cell anemia patients. *Microvasc Res* 90, 173-179
 853 (2013).
- K. Asare *et al.*, Plasma interleukin-1beta concentration is associated with stroke in sickle
 cell disease. *Cytokine* 49, 39-44 (2010).
- 55. B. A. Cerqueira, W. V. Boas, A. D. Zanette, M. G. Reis, M. S. Goncalves, Increased
- 857 concentrations of IL-18 and uric acid in sickle cell anemia: contribution of hemolysis,
- endothelial activation and the inflammasome. *Cytokine* **56**, 471-476 (2011).
- 859 56. N. Conran et al., Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-
- 860 protein kinase A dependent pathway in neutrophils from sickle cell disease patients. *Br J*
- 861 *Haematol* **139**, 148-158 (2007).
- 862 57. M. Zachlederova, P. Jarolim, The dynamics of gene expression in human lung
- 863 microvascular endothelial cells after stimulation with inflammatory cytokines. *Physiol Res*864 **55**, 39-47 (2006).
- 865 58. N. Patel *et al.*, Placenta growth factor (PIGF), a novel inducer of plasminogen activator
 866 inhibitor-1 (PAI-1) in sickle cell disease (SCD). *J Biol Chem* 285, 16713-16722 (2010).
- 867 59. M. Lamkanfi, Emerging inflammasome effector mechanisms. *Nat Rev Immunol* **11**, 213868 220 (2011).
- 869 60. V. A. Rathinam, K. A. Fitzgerald, Inflammasome Complexes: Emerging Mechanisms and
 870 Effector Functions. *Cell* 165, 792-800 (2016).
- 871 61. F. Bauernfeind, V. Hornung, Of inflammasomes and pathogens--sensing of microbes by
 872 the inflammasome. *EMBO Mol Med* 5, 814-826 (2013).
- 873 62. K. Midtbo, D. Eklund, E. Sarndahl, A. Persson, Molecularly Distinct NLRP3 Inducers
- 874 Mediate Diverse Ratios of Interleukin-1beta and Interleukin-18 from Human Monocytes.
- 875 *Mediators Inflamm* **2020**, 4651090 (2020).

876 63. N. M. de Vasconcelos, M. Lamkanfi, Recent Insights on Inflammasomes, Gasdermin Pores, and Pyroptosis. Cold Spring Harb Perspect Biol 12 (2020). 877 878 A. H. Chan, K. Schroder, Inflammasome signaling and regulation of interleukin-1 family 64. 879 cytokines. J Exp Med 217 (2020). 880 65. T. Satoh, A. Otsuka, E. Contassot, L. E. French, The inflammasome and IL-1beta: 881 implications for the treatment of inflammatory diseases. Immunotherapy 7, 243-254 882 (2015). 883 66. M. C. Durpes et al., Effect of interleukin-8 and RANTES on the Gardos channel activity 884 in sickle human red blood cells: role of the Duffy antigen receptor for chemokines. Blood 885 Cells Mol Dis 44, 219-223 (2010). 886 67. M. C. Durpes et al., Activation state of alpha4beta1 integrin on sickle red blood cells is 887 linked to the duffy antigen receptor for chemokines (DARC) expression. J Biol Chem 888 **286**, 3057-3064 (2011). 889 68. D. Bratosin et al., Programmed cell death in mature erythrocytes: a model for 890 investigating death effector pathways operating in the absence of mitochondria. Cell 891 Death Differ 8, 1143-1156 (2001). 892 69. E. Nader, M. Romana, P. Connes, The Red Blood Cell-Inflammation Vicious Circle in 893 Sickle Cell Disease. Front Immunol 11, 454 (2020). 894 70. T. Jang et al., Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary 895 events. J Transl Med 19, 397 (2021). 896 71. A. U. Zaidi et al., A systematic literature review of frequency of vaso-occlusive crises in 897 sickle cell disease. Orphanet J Rare Dis 16, 460 (2021). 898 72. S. Veluswamy et al., Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation 899 of the Microvasculature the Trigger? J Clin Med 8 (2019). 900 73. M. Shimizu, S. Takei, M. Mori, A. Yachie, Pathogenic roles and diagnostic utility of 901 interleukin-18 in autoinflammatory diseases. Front Immunol 13, 951535 (2022).

- 902 74. D. Pilat *et al.*, Blockade of IL-18 signaling diminished neuropathic pain and enhanced the
 903 efficacy of morphine and buprenorphine. *Mol Cell Neurosci* **71**, 114-124 (2016).
- M. Garzon-Tituana *et al.*, Granzyme A inhibition reduces inflammation and increases
 survival during abdominal sepsis. *Theranostics* **11**, 3781-3795 (2021).
- R. R. da Silva *et al.*, Evaluation of Th17 related cytokines associated with clinical and
 laboratorial parameters in sickle cell anemia patients with leg ulcers. *Cytokine* 65, 143147 (2014).
- G. Ndrepepa, Myeloperoxidase A bridge linking inflammation and oxidative stress with
 cardiovascular disease. *Clin Chim Acta* 493, 36-51 (2019).
- 911 78. H. Zhang *et al.*, Inhibition of myeloperoxidase decreases vascular oxidative stress and

912 increases vasodilatation in sickle cell disease mice. *J Lipid Res* **54**, 3009-3015 (2013).

- 913 79. A. M. Brandow *et al.*, Children and adolescents with sickle cell disease have worse cold
 914 and mechanical hypersensitivity during acute painful events. *Pain* **160**, 407-416 (2019).
- 915 80. P. Chalacheva *et al.*, Autonomic responses to cold face stimulation in sickle cell disease:
 916 a time-varying model analysis. *Physiol Rep* **3** (2015).
- 917 81. P. Shah *et al.*, Mental stress causes vasoconstriction in subjects with sickle cell disease
 918 and in normal controls. *Haematologica* **105**, 83-90 (2020).
- 91982.M. J. Telen *et al.*, Alloimmunization in sickle cell disease: changing antibody specificities920and association with chronic pain and decreased survival. *Transfusion* **55**, 1378-1387
- 921 (2015).
- 83. T. Wun, The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell
 Disease; Haemoglobinopathy. *Hematology* 5, 403-412 (2001).
- 924